Introduction
Octanate IV Infusion 500 IU/10 ml is a blood-clotting protein used in the treatment and prevention of bleeding episodes in individuals with hemophilia A. Hemophilia A is a genetic disorder characterized by the deficiency of Factor VIII, which is essential for blood clotting. Replacement therapy with Octanate IV Infusion 500 IU/10 ml helps to restore normal clotting and prevent excessive bleeding, particularly in situations such as surgery, trauma, or spontaneous bleeds.
Uses
Octanate IV Infusion 500 IU/10 ml is used for:
- Treatment and prevention of bleeding episodes in individuals with hemophilia A.
- Prophylaxis to prevent or reduce the frequency of bleeding episodes.
- Control of bleeding during surgical procedures in hemophilia A patients.
- Replacement therapy in acquired Factor VIII deficiency.
| Brand Name | Octanate |
|---|---|
| Type | IV Infusion |
| Weight | 500 IU/10 ml |
| Generic | Human Coagulation Factor VIII |
| Manufacturer | City Overseas Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Factor VIII is a glycoprotein that plays a critical role in the coagulation cascade, specifically in the intrinsic pathway of blood clotting. It acts as a cofactor for Factor IX, which activates Factor X, leading to the conversion of prothrombin to thrombin and eventually the formation of a fibrin clot. In individuals with hemophilia A, the absence or dysfunction of Factor VIII leads to impaired clot formation and uncontrolled bleeding. Administering exogenous Octanate IV Infusion 500 IU/10 ml restores the clotting function by compensating for the deficient endogenous factor.
How Long Does It Take to Work?
Octanate IV Infusion 500 IU/10 ml begins working immediately upon administration, with an onset of action typically within minutes to an hour. The duration of action depends on the dose and the severity of the bleeding episode but generally lasts for several hours to a day.
Absorption
Octanate IV Infusion 500 IU/10 ml is administered intravenously and is immediately available in the bloodstream. The absorption phase is bypassed due to the intravenous route, ensuring rapid availability for clotting.
Route of Elimination
Octanate IV Infusion 500 IU/10 ml is eliminated primarily through protein catabolism in the reticuloendothelial system. It is not excreted in the urine or feces in significant amounts.
Dosage
Dosage for the prevention of bleeding: If you suffer from severe haemophilia A you should inject 20 to 40 IU of factor VIII per kg body weight every two or three days for long-term prevention. Your dosage should be adjusted according to your response. In some cases shorter dosage intervals or higher dosages may be necessary.Dosage calculation: Always use Octanate exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Factor VIII activity refers to the amount of factor VIII present in the plasma. It is expressed either as a percentage (relative to normal human blood plasma) or in International Units (IU). The dosage of factor VIII is expressed in IU. One IU of factor VIII activity is equivalent to the amount of factor VIII in one ml of normal human blood plasma. One IU of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5%-2% of normal activity. To calculate your dosage, the level of factor VIII activity in your blood plasma is measured. This will indicate by how much the activity needs to be increased. Please consult your doctor if you are uncertain how much your factor VIII activity has to be increased or how to calculate your dosage.
Dosage varies depending on the severity of the condition, the patient's weight, and the clinical situation:
- On-Demand Treatment: 20-50 IU/kg of body weight, depending on the severity of the bleeding episode.
- Prophylaxis: 25-40 IU/kg, administered two to three times weekly to prevent bleeding episodes.
- Surgical Procedures: Dosages vary depending on the type and complexity of surgery, with higher doses required for major surgery.
Administration
Octanate IV Infusion 500 IU/10 ml is administered intravenously, either as a slow injection or an infusion, depending on the clinical need. It is typically given in a hospital or clinical setting but can be administered at home by trained individuals for prophylaxis or on-demand treatment.
Side Effects
Common side effects of Octanate IV Infusion 500 IU/10 ml include:
- Injection site reactions (pain, redness, or swelling).
- Headache.
- Nausea.
- Dizziness or lightheadedness.
Toxicity
Octanate IV Infusion 500 IU/10 ml is generally safe when administered at therapeutic doses. However, high doses or repeated administration can lead to the development of neutralizing antibodies (inhibitors) against Factor VIII, reducing its efficacy and making it difficult to control bleeding. Patients with inhibitors may require additional treatments or higher doses to achieve adequate clotting.
Precautions
Precautions should be taken in patients with known allergies to Factor VIII or any of the components of the formulation. Patients should also be monitored for the development of inhibitors, especially those who have previously been treated with Factor VIII. Individuals with liver or kidney disease may require dosage adjustments or additional monitoring.
Interaction
There are no significant drug interactions associated with Octanate IV Infusion 500 IU/10 ml. However, caution should be exercised when using other blood products or anticoagulants concurrently, as they may affect the coagulation system.
Disease Interaction
Octanate IV Infusion 500 IU/10 ml should be used with caution in patients with:
- Liver disease, as it can affect the metabolism and clearance of the factor.
- Kidney disease, which may necessitate dosage adjustments.
- Previous history of Factor VIII inhibitors, as they may decrease treatment efficacy.
Drug Interaction
There are no major drug interactions associated with Octanate IV Infusion 500 IU/10 ml. However, anticoagulants, such as warfarin or heparin, should be used cautiously, as they can counteract the effects of Factor VIII and increase the risk of bleeding.
Food Interactions
There are no known significant food interactions with Octanate IV Infusion 500 IU/10 ml. Diet does not affect the efficacy or absorption of the medication since it is administered intravenously.
Pregnancy Use
There is limited data on the use of Octanate IV Infusion 500 IU/10 ml during pregnancy. It should be used during pregnancy only if clearly needed, and the potential benefits outweigh the risks. Pregnant women with hemophilia or carriers of the hemophilia gene should be closely monitored, and prophylactic treatment may be considered during delivery.
Lactation Use
It is not known whether Octanate IV Infusion 500 IU/10 ml is excreted in human milk. Caution should be exercised when administering the medication to breastfeeding women, and the potential benefits to the mother should be weighed against the potential risks to the infant.
Acute Overdose
Overdose of Octanate IV Infusion 500 IU/10 ml is rare but can lead to the development of inhibitors or thrombotic events, especially in patients with other risk factors for clotting disorders. In cases of overdose, treatment should be discontinued, and the patient should be monitored for signs of thrombosis or the development of inhibitors.
Contraindication
Octanate IV Infusion 500 IU/10 ml is contraindicated in individuals with:
- Known hypersensitivity to Factor VIII or any of its components.
- Severe allergic reactions (e.g., anaphylaxis) to previous treatments with Factor VIII.
Use Direction
Octanate IV Infusion 500 IU/10 ml should be administered according to the prescribed dosage and schedule. The infusion should be given slowly, and patients should be monitored for any adverse reactions during and after the administration. It is crucial to follow all instructions for reconstitution and administration carefully to ensure the efficacy of the treatment.
Storage Conditions
Octanate IV Infusion 500 IU/10 ml should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. The product should not be frozen, and it should be used within a certain period after reconstitution (typically a few hours). Once opened, it should be used immediately and discarded if not used within the recommended timeframe.
Volume of Distribution
The volume of distribution for Octanate IV Infusion 500 IU/10 ml is approximately 0.05-0.07 L/kg. This relatively low volume of distribution indicates that Factor VIII remains primarily in the vascular space, where it is needed for its clotting activity.
Half Life
The half-life of Octanate IV Infusion 500 IU/10 ml is typically 8-12 hours in adults, although it may be shorter in children. In individuals with hemophilia A, the half-life may vary depending on the presence of inhibitors and the patient's individual pharmacokinetics.
Clearance
The clearance of Octanate IV Infusion 500 IU/10 ml is approximately 3-5 mL/kg/hr in individuals without inhibitors. Clearance is influenced by factors such as body weight, liver function, and the presence of inhibitors. Reduced clearance may be seen in neonates and individuals with impaired liver function.
See in details version Octanate IV Infusion 500 IU/10 ml also Octanate IV Infusion 500 IU/10 ml in bangla
